New chemo combo shows promise in breast cancer trial
NCT ID NCT06513364
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new chemotherapy drug called WH002 against the standard drug paclitaxel in 40 women with HER2-negative breast cancer. Both drugs were given before surgery, followed by two other chemotherapy drugs. The main goal was to compare side effects and how well the tumors responded. The trial has been completed, and results will help determine if WH002 is a safer or more effective option.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Beijing, Beijing Municipality, 100021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?